Jianqin Xu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Jianqin Xu has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
Shengnan Cui
Department of Hematology, The Second Affiliated Hospital, Shaanxi University of Chinese Medicine, Xianyang, Shaanxi 712046, P.R. China
1 shared publicationWenbin Li
Department of Dermatology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi'an, Shaanxi 710003, P.R. China
1 shared publication- Xiaoning Yan
Department of Dermatology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi'an, 710003, China
1 shared publication Yiding Zhao
Department of Dermatology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi'an, Shaanxi 710003, P.R. China
1 shared publicationYong Liu
Department of Dermatology, Shaanxi Provincial Hospital of Traditional Chinese Medicine, Xi'an, Shaanxi 710003, P.R. China
1 shared publication
Latest Publications
- Open Access
- 18 March 2019
- Published by Spandidos Publications in Oncology Letters
- Vol. 17 (6) , 4985-4993
PAX3 is a biomarker and prognostic factor in melanoma: Database mining
Paired box 3 (PAX3) is a transcription factor and critical regulator of pigment cell development during embryonic development. However, while there have been several studies on PAX3, its expression patterns and precise role remain to be clarified. The present study is an in‑depth computational study of tumor‑associated gene information, with specific emphasis on the expression of PAX3 in melanoma, using Oncomine along with an investigation of corresponding expression profiles in an array of cancer cell lines through Cancer Cell Line Encyclopedia analysis. Based on Kaplan‑Meier analysis, the prognostic value of high PAX3 expression in tissues from patients with melanoma compared with normal tissues was assessed. PAX3 was more highly expressed in male patients with melanoma compared with female patients with melanoma. Using Oncomine and Coexpedia analysis, it was demonstrated that PAX3 expression was clearly associated with SRY‑box 10 expression. The survival analysis results revealed that high PAX3 mRNA expression was associated with worse survival rates in patients with melanoma. These results suggested that PAX3 may be a biomarker and essential prognostic factor for melanoma, and provided an important theoretical basis for the development of melanoma treatments.
- 18 March 2019
- Published by Spandidos Publications in Oncology Letters
- Vol. 17 (6) , 4985-4993
Open AccessPAX3 is a biomarker and prognostic factor in melanoma: Database mining
Paired box 3 (PAX3) is a transcription factor and critical regulator of pigment cell development during embryonic development. However, while there have been several studies on PAX3, its expression patterns and precise role remain to be clarified. The present study is an in‑depth computational study of tumor‑associated gene information, with specific emphasis on the expression of PAX3 in melanoma, using Oncomine along with an investigation of corresponding expression profiles in an array of cancer cell lines through Cancer Cell Line Encyclopedia analysis. Based on Kaplan‑Meier analysis, the prognostic value of high PAX3 expression in tissues from patients with melanoma compared with normal tissues was assessed. PAX3 was more highly expressed in male patients with melanoma compared with female patients with melanoma. Using Oncomine and Coexpedia analysis, it was demonstrated that PAX3 expression was clearly associated with SRY‑box 10 expression. The survival analysis results revealed that high PAX3 mRNA expression was associated with worse survival rates in patients with melanoma. These results suggested that PAX3 may be a biomarker and essential prognostic factor for melanoma, and provided an important theoretical basis for the development of melanoma treatments.